Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 156, Issue 1-2, Pages 3-9Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2004.02.016
Keywords
laquinimod; experimental autoimmune encephalomyelitis; Lewis rats
Categories
Ask authors/readers for more resources
The new orally active drug laquinimod (ABR-215062) was evaluated in experimental autoimmune encephalomyelitis (EAE) in the Lewis rat. EAE shares important immunological and clinical features with multiple sclerosis (MS). Doses of 16, 1.6 and 0.16 mg/kg/day laquinimod dose-dependently inhibited disease and showed better disease inhibitory effects as compared to roquinimex (Linomide). Furthermore, laquinimod inhibited the inflammation of both CD4(+) T cells and macrophages into central nervous tissues, i.e. the spinal cord. It also changed the cytokine balance in favour of T(H)2/T(H)3 cytokines IL-4, IL-10 and TGF-beta. Laquinimod therefore represents a new orally active immunoregulatory drug without general immunosuppressive properties with a potential for the treatment of severe autoimmune diseases like MS. (C) 2004 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available